# Fitlife Brands, Inc.: Form 10-Q for the period ended Sep 30, 2012

- Company: [Fitlife Brands, Inc.](/companies/ftlf.md) (CIK 1374328)
- Form: 10-Q
- Filed: 2012-11-14
- Accepted by EDGAR: Nov 14, 2012, 14:46 ET
- Period: 2012-09-30
- Accession: 0001415889-12-001677
- Inline XBRL: yes
- Main document: https://www.sec.gov/Archives/edgar/data/1374328/000141588912001677/bnlb10q09302012.htm
- All documents and exhibits: https://www.sec.gov/Archives/edgar/data/1374328/000141588912001677/

## Figures reported in this filing

Standardized XBRL line items for the period ended 2012-09-30.

| Line item | Period | Value | XBRL concept |
| --- | --- | ---: | --- |
| Revenue | 3 months, 2012-07-01 to 2012-09-30 | $4.6m | us-gaap:Revenues |
| Revenue | 9 months, 2012-01-01 to 2012-09-30 | $14.7m | us-gaap:Revenues |
| Cost of revenue | 3 months, 2012-07-01 to 2012-09-30 | $3.0m | us-gaap:CostOfGoodsSold |
| Cost of revenue | 9 months, 2012-01-01 to 2012-09-30 | $9.4m | us-gaap:CostOfGoodsSold |
| Gross profit | 3 months, 2012-07-01 to 2012-09-30 | $1.6m | us-gaap:GrossProfit |
| Gross profit | 9 months, 2012-01-01 to 2012-09-30 | $5.4m | us-gaap:GrossProfit |
| Operating income | 3 months, 2012-07-01 to 2012-09-30 | $469.4k | us-gaap:OperatingIncomeLoss |
| Operating income | 9 months, 2012-01-01 to 2012-09-30 | $2.0m | us-gaap:OperatingIncomeLoss |
| Interest expense | 3 months, 2012-07-01 to 2012-09-30 | −$4.6k | us-gaap:InterestExpense |
| Interest expense | 9 months, 2012-01-01 to 2012-09-30 | −$13.9k | us-gaap:InterestExpense |
| Income tax | 3 months, 2012-07-01 to 2012-09-30 | $5.5k | us-gaap:IncomeTaxExpenseBenefit |
| Net income | 3 months, 2012-07-01 to 2012-09-30 | $472.9k | us-gaap:NetIncomeLoss |
| Net income | 9 months, 2012-01-01 to 2012-09-30 | $2.0m | us-gaap:NetIncomeLoss |
| Diluted EPS | 3 months, 2012-07-01 to 2012-09-30 | $0.00 | us-gaap:EarningsPerShareDiluted |
| Diluted EPS | 9 months, 2012-01-01 to 2012-09-30 | $0.02 | us-gaap:EarningsPerShareDiluted |
| Basic EPS | 3 months, 2012-07-01 to 2012-09-30 | $0.01 | us-gaap:EarningsPerShareBasic |
| Basic EPS | 9 months, 2012-01-01 to 2012-09-30 | $0.03 | us-gaap:EarningsPerShareBasic |
| Diluted shares (weighted) | 3 months, 2012-07-01 to 2012-09-30 | 94,982,968 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Diluted shares (weighted) | 9 months, 2012-01-01 to 2012-09-30 | 95,117,313 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Operating cash flow | 9 months, 2012-01-01 to 2012-09-30 | $832.4k | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Cash and equivalents | at 2012-09-30 | $1.2m | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | at 2012-09-30 | $5.2m | us-gaap:AssetsCurrent |
| Total assets | at 2012-09-30 | $6.6m | us-gaap:Assets |
| Current liabilities | at 2012-09-30 | $1.3m | us-gaap:LiabilitiesCurrent |
| Total liabilities | at 2012-09-30 | $1.3m | us-gaap:Liabilities |
| Shareholders' equity | at 2012-09-30 | $5.2m | us-gaap:StockholdersEquity |

## Management's discussion and analysis

As filed, 11,185 characters.

### Forward-Looking Statements

Management’s Discussion and Analysis contains various “forward looking statements” within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, regarding future events or the future financial performance of the Company that involve risks and uncertainties. Certain statements included in this Form 10-Q, including, without limitation, statements related to anticipated cash flow sources and uses, and words including but not limited to “anticipates”, “believes”, “plans”, “expects”, “future” and similar statements or expressions, identify forward looking statements. Any forward-looking statements herein are subject to certain risks and uncertainties in the Company’s business, including but not limited to, reliance on key customers and competition in its markets, market demand, product performance, technological developments, maintenance of relationships with key suppliers, difficulties of hiring or retaining key personnel and any changes in current accounting rules, all of which may be beyond the control of the Company. The Company adopted at management’s discretion, the most conservative recognition of revenue based on the most astringent guidelines of the SEC. Management will elect additional changes to revenue recognition to comply with the most conservative SEC recognition on a forward going accrual basis as the model is replicated with other similar markets. The Company’s actual results could differ materially from those anticipated in these forward-looking statements as a result of certain factors, including those set forth therein.

Forward-looking statements involve risks, uncertainties and other factors, which may cause our actual results, performance or achievements to be materially different from those expressed or implied by such forward-looking statements. Factors and risks that could affect our results and achievements and cause them to materially differ from those contained in the forward-looking statements include those identified in the section titled “Risk Factors” in the Company’s Annual Report on Form 10-K for the year ended December 31, 2011, as well as other factors that we are currently unable to identify or quantify, but that may exist in the future.

In addition, the foregoing factors may affect generally our business, results of operations and financial position. Forward-looking statements speak only as of the date the statement was made. We do not undertake and specifically decline any obligation to update any forward-looking statements.

### Overview

Bond Laboratories, Inc. (the “*Company”*) is a national provider of innovative and proprietary nutritional supplements for health conscious consumers. The Company produces and markets its products through NDS Nutrition Products, Inc., a Florida corporation (“*NDS”*). NDS manufactures and distributes a full line of nutritional supplements to support healthy living predominantly through franchisees of General Nutrition Centers, Inc. (“*GNC”*) located throughout the United States.

The Company was incorporated in the State of Nevada on July 26, 2005. In October 2008, the Company acquired the assets of NDS Nutritional Products, Inc., a Nebraska corporation, and moved those assets into its wholly owned subsidiary NDS.

Bond Laboratories is headquartered in Omaha, Nebraska. For more information on the Company, please go to http://www.bond-labs.com. The Company’s Common Stock currently trades under the symbol BNLB on the OTCQB market.

### Results of Operations

*Net Sales.* Revenue for the three months ended September 30, 2012 increased to $4,591,183 as compared to $3,219,792 for the three months ended September 30, 2011. Revenues for the nine months ended September 30, 2012 increased to $14,722,334 as compared to $9,378,573 for the nine months ended September 30, 2011. This increase was primarily driven by continued strong sales of recently introduced products, greater average sales per retail location, and the recent introduction of our products in international markets. We currently market 47 products to over 900 GNC franchise locations nationwide, and 10 products internationally to GNC franchise locations in four countries. The Company continually seeks to increase both the number of stores and number of approved products that comprise its distribution footprint and, while no assurances can be given, anticipates that such efforts will continue to drive future revenue growth. While not a material component of revenue for this quarter, management anticipates that continued international expansion will be a major driver of future growth.

During the quarter ended September 30, 2012, approximately 1.5% of the Company’s revenue was attributable to products containing DMAA. The Company reintroduced such products with a new formulation excluding DMAA during the quarter ending June 30, 2012, and continued to sell products containing this new formulation during the quarter ending September 30, 2012. In the event the reformulated products do not generate the level of sales as compared to the products they replaced containing DMAA, and such decrease in product sales is not otherwise offset by sales attributable to new products introduced by the Company, the Company’s net sales may be affected, and such affect may be material.

*Cost of Goods Sold.* Cost of goods sold for the three months ended September 30, 2012 increased to $2,956,672 as compared to $2,021,204 for the three months ended September 30, 2011. Cost of goods sold for the nine months ended September 30, 2012 increased to $9,365,222 as compared to $5,987,768 for the nine months ended September 30, 2011. The increase was primarily attributable to increased sales volume during the quarter.

*General and Administrative Expense.* General and administrative expense for the three months ended September 30, 2012 increased to $451,271 as compared to $332,932 for the three months ended September 30, 2011. General and administrative expense for the nine months ended September 30, 2012 increased to $1,570,408 as compared to $1,146,550 for the nine months ended September 30, 2011. The increase in general and administrative expense is primarily attributable to higher personnel costs associated with our continued growth and legal costs and expenses incurred in connection with the Schick Litigation. Management currently anticipates that legal costs and expenses in subsequent periods will substantially decrease, resulting in lower general and administrative expense subsequent to the quarter ended September 30, 2013 compared to the quarter ended September 30, 2012.

*Selling and Marketing Expense.* Selling and marketing expense for the three months ended September 30, 2012 increased to $653,151 as compared to $501,316 for the three months ended September 30, 2011. Selling and marketing expense for the nine months ended September 30, 2012 increased to $1,635,677 as compared to $1,234,408 for the nine months ended September 30, 2011. The increase in selling and marketing expense is principally attributable to expanded marketing activities designed to support current and expected future revenue growth, which includes costs most notably driven by increased product sales made in connection with the Company’s participation in GNC’s annual franchise convention. As net sales increase, selling and marketing expense is anticipated to simultaneously increase, although management does not anticipate that selling and marketing expense will increase at the same rate.

*Depreciation and Amortization.* Depreciation and amortization for the three months ended September 30, 2012 decreased to $60,640 as compared to $66,561 for the three months ended September 30, 2011. Depreciation and amortization for the nine months ended September 30, 2012 decreased to $183,911 as compared to $200,704 for the nine months ended 30, 2011.

*Net Income/(Loss).* We generated a profit of $467,409 for the three months ended September 30, 2012 as compared to a profit of $290,571 for the three months ended September 30, 2011. We generated a profit of $1,960,265 for the nine months ended September 30, 2012 as compared to a profit of $782,288 for the nine months ended September 30, 2011. The increase was driven by greater sales volume at sustained margins together with ongoing cost control programs.

### Liquidity and Capital Resources

The Company has historically financed its operations primarily through equity and debt financings. The Company has also provided for its cash needs by issuing common stock, options and warrants for certain operating costs, including consulting and professional fees. The Company did not engage in any financing activities during the nine month period ended September 30, 2012. Together with anticipated cash derived from operations, our existing cash resources are expected to provide for the Company’s liquidity through at least December 31, 2012. Although no assurances can be given, management currently believes the Company will generate sufficient cash from operations to provide for its working capital needs beyond December 31, 2012.

*Cash Provided by/(Used in) Operations.* Our cash provided by operating activities for the nine months ended September 30, 2012 was 832,440 as compared to cash used by operating activities of $1,546 for the nine months ended September 30, 2011. The increase is mainly attributable to increased net income. Cash provided by operations during the nine months ended September 30, 2012 included $210,000 in payments in connection with the settlement of the Schick Litigation. We anticipate using an additional $45,000 in cash through December 31, 2012 in connection with the settlement of the Schick Litigation; however, management nevertheless anticipates reporting positive cash provided by operations during the fourth quarter, and for the year ended December 31, 2012.

*Cash Provided by/(Used in) Investing Activities.* Cash provided by investing activities for the nine months ended September 30, 2012 was $0 as compared to $1,200 for the nine months ended September 30, 2011.

*Cash Provided by/(Used in) Financing Activities.* Our cash used in financing activities for the nine months ended September 30, 2012 was $0 as compared to cash used in financing activities of $146,153 for the nine months ended September 30, 2011. The improvement is attributable to the retirement of previously issued acquisition-related debt.

### WHERE YOU CAN FIND MORE INFORMATION

You are advised to read this Quarterly Report on Form 10-Q in conjunction with other reports and documents that we file from time to time with the SEC. In particular, please read our Quarterly Reports on Form 10-Q, Annual Report on Form 10-K, and Current Reports on Form 8-K that we file from time to time. You may obtain copies of these reports directly from us or from the SEC at the SEC’s Public Reference Room at 100 F. Street, N.E. Washington, D.C. 20549, and you may obtain information about obtaining access to the Reference Room by calling the SEC at 1-800-SEC-0330. In addition, the SEC maintains information for electronic filers at its website http://www.sec.gov.

## Market risk

As filed, 1,411 characters.

Our business is currently conducted principally in the United States. As a result, our financial results are not affected by factors such as changes in foreign currency exchange rates or economic conditions in foreign markets. We do not engage in hedging transactions to reduce our exposure to changes in currency exchange rates, although if the geographical scope of our business broadens, we may do so in the future.

Our exposure to risk for changes in interest rates relates primarily to our investments in short-term financial instruments. Investments in both fixed rate and floating rate interest earning instruments carry some interest rate risk. The fair value of fixed rate securities may fall due to a rise in interest rates, while floating rate securities may produce less income than expected if interest rates fall. Partly as a result of this, our future interest income may fall short of expectations due to changes in interest rates or we may suffer losses in principal if we are forced to sell securities that have fallen in estimated fair value due to changes in interest rates. However, as substantially all of our cash equivalents consist of bank deposits and short-term money market instruments, we do not expect any material change with respect to our net income as a result of an interest rate change.

We do not hold any derivative instruments and do not engage in any hedging activities.

## Controls and procedures

As filed, 3,992 characters.

(a) *Evaluation of Disclosure Controls and Procedures*

We maintain disclosure controls and procedures that are designed to ensure that information required to be disclosed in our Exchange Act reports is recorded, processed, summarized and reported within the time periods specified in the Securities and Exchange Commission’s rules and forms and that such information is accumulated and communicated to our Chief Executive Officer and Chief Financial Officer, as appropriate, to allow for timely decisions regarding required disclosure. In designing and evaluating the disclosure controls and procedures, management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving the desired control objectives, and management is required to apply its judgment in evaluating the cost-benefit relationship of possible controls and procedures. Our disclosure controls and procedures were designed to provide reasonable assurance that the controls and procedures would meet their objectives. As required by SEC Rule 13a-15(b), our Chief Executive Officer and Chief Financial Officer carried out an evaluation of the effectiveness of the design and operation of our disclosure controls and procedures as of the end of the period covered by this report. Based on the foregoing, our Chief Executive Officer and Chief Financial Officer concluded that our disclosure controls and procedures were effective at the reasonable assurance level.

Our Chief Executive Officer and Chief Financial Officer are responsible for establishing and maintaining adequate internal control over our financial reporting. In order to evaluate the effectiveness of internal control over financial reporting, as required by Section 404 of the Sarbanes-Oxley Act, management has conducted an assessment, including testing, using the criteria in Internal Control — Integrated Framework, issued by the Committee of Sponsoring Organizations of the Treadway Commission (“*COSO”*). Our system of internal control over financial reporting is designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles. Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Management has used the framework set forth in the report entitled Internal Control-Integrated Framework published by the COSO to evaluate the effectiveness of our internal control over financial reporting. Based on this assessment, our Chief Executive Officer and Chief Financial Officer have concluded that our internal control over financial reporting was effective as of September 30, 2012. This Quarterly Report does not include an attestation report of our independent registered public accounting firm regarding internal control over financial reporting. Our internal control over financial reporting was not subject to attestation by our independent registered public accounting firm pursuant to temporary rules of the SEC that permit us to provide only management’s report in this Quarterly Report. There has been no change in our internal controls over financial reporting during our most recent fiscal quarter that has materially affected, or is reasonably likely to materially affect, our internal controls over financial reporting.

(b) *Changes in Internal Controls Over Financial Reporting*

There have been no changes in our internal controls over financial reporting or in other factors that could materially affect, or are reasonably likely to affect, our internal controls over financial reporting during the quarter ended September 30, 2012. There have not been any significant changes in the Company's critical accounting policies identified since the Company filed its Annual Report on Form 10-K as of December 31, 2011.

### PART II

### OTHER INFORMATION

## Risk factors

As filed, 1,813 characters.

In addition to the risk factors previously disclosed in Part II, Item 6, “Risk Factors” in our Annual Report on Form 10-K for the year ended December 31, 2011, the Company has identified the following additional risk factor:

***Certain of the Company’s products contain Dimethylamylamine (“DMAA”), the safety of which has been questioned by the FDA. Any product liability associated with DMAA could expose us to significant risks.***

Several of the Company’s products contain DMAA, which has been extensively marketed as a pre-workout sports supplement. It has been reported that DMAA has potential side effects, including headache, nausea, and stroke. At least one distributor of DMAA has been named in a class action lawsuit over DMAA’s safety. The FDA recently sent warning letters to ten manufacturers and distributors of DMAA challenging the marketing of products containing DMAA for lack of evidence of safety, and stating that DMAA was not a dietary ingredient and is not, therefore, eligible to be used as an active ingredient in dietary supplements. While the Company believes there is no basis for the FDA's action, and that DMAA is safe in the quantities included in the Company's products, until further studies are conducted or further action is taken by the FDA, no assurances can be given. The Company has nevertheless recently reformulated its products containing DMAA, reintroduced products with a new formulation excluding DMAA during the quarter ending June 30, 2012, and continued to sell products containing this new formulation during the quarter ending September 30, 2012. Although we maintain product liability insurance, it may not be sufficient to cover any product liability claims that may arise from the use of our products containing DMAA, if such claims are successfully asserted.

Filed Nov 14, 2012.
Source: SEC EDGAR, the filing index for accession 0001415889-12-001677. Last ingested by Listed: Oct 24, 2026, 15:09 ET. No prices; not investment advice.
